Advancements in personalized medicine and other innovations are transforming the way dosage forms are viewed.

Reshaping Dosage Forms

This study aimed to develop a taste-masked drug resin complex using the ion exchange resin Kyron T-114.

Development of Taste-Masked Oral Dispersible Tablets of Cefpodoxime Proxetil

Novel genetic engineering technologies are transforming the design and manufacture of bispecific antibodies, which are emerging as a promising new class of biologics.

Frontrunners in Bispecific Antibodies

Topic

Articles

Sartorius Stedim Biotech will supply equipment for Penn State’s new Fermentation Facility in the university’s Center of Excellence in Industrial Biotechnology. 

Sartorius Stedim Biotech and Penn State University Announce Biotechnology Partnership

The new facility, to be built in Toronto, Canada, will significantly increase capacity for pediatric and booster vaccines. 

Sanofi to Invest Roughly $430 Million in Canadian Vaccine Facility

Hallie Forcinio is packing editor for Pharmaceutical Technology and Pharmaceutical Technology Europe, editorhal@sbcglobal.net.

New filling and inspection machines and new containers and closures for injectable drugs will be on display at INTERPHEX 2018.

Parenteral Packaging Innovations

The biopharmaceutical firm has chosen Rhode Island as the site of its next-generation biomanufacturing plant, which will offer flexibility, speed, and efficiency.

Amgen to Build Next-Generation Biomanufacturing Plant

The new 300,000-square-foot facility is considered the largest dedicated cell and gene therapy manufacturing facility with fully integrated services.

Lonza Opens Dedicated Cell and Gene Therapy Manufacturing Facility

Roche has acquired a program to develop regenerative therapies for multiple sclerosis.

Roche Acquires Regenerative Medicines Program

Under this global collaboration, the companies will develop encapsulated cell therapies for treating Type 1 diabetes.

Lilly, Sigilon Partner on Encapsulated Cell Therapies for Diabetes

Celltrion received complete response letters from FDA for its rituximab and trastuzumab biosimilars.

FDA Issues CRLs to Celltrion for Two Biosimilars

Anthony Qu, PhD, vice president of Scientific Affairs at Halo Pharma, will give a presentation on fixed-dose combination products, drug products containing multiple active ingredients, as an effective approach for simplified dosing at CPhI North America on Wednesday, April 25, 2018 in Philadelphia, PA.

Halo Pharma Shows Fixed-Dose Combination Products are Effective for Simplified Dosing

Boehringer Ingelheim and OSE Immunotherapeutics have entered a global immuno-oncology partnership to develop a checkpoint inhibitor for treating advanced solid tumors.